Genovax, Mediolanum Farmaceutici deal

Pharma Mediolanum acquired cancer vaccine GX301 from Genovax. Mediolanum will be responsible for developing and commercializing GX301, while Genovax will consult. Genovax will receive an undisclosed upfront payment and is eligible for milestones, plus royalties.

The telomerase-based vaccine completed a Phase I trial in prostate and renal cancer patients in February. According to Eporgen Ventures, which contributed seed funding to Genovax, a Phase II trial in prostate cancer patients is expected to begin next half. The companies, which did not disclose financial details, could not be reached for details. ...